PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND,...